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Specialty Update has been developed in collaboration with the Council of Musculoskeletal Specialty
Societies (COMSS) of the American Academy of Orthopaedic Surgeons.
Specialty Update
What’s New in 
Orthopaedic Research
BY MATTHEW J. SILVA, PHD, AND LINDA J. SANDELL, PHD
The last year has brought substantial advances in many areas 
of orthopaedic research. Probably the most impressive is the 
shift from a focus on implant design, obviously the most suc-
cessful treatment of end-stage degenerative joint disease, to 
the potential for earlier interventions, or “biological solu-
tions,” that could increase the life of the cartilage, bone, ten-
dons, and ligaments of the joint. The search for biological 
solutions touches on all aspects of orthopaedic research: re-
sponse to implant materials, development of tissue-engineered 
cartilage and bone, and discovery of biomarkers for joint dis-
ease. We will review some of the latest advances made and 
questions raised in this new age of orthopaedic research.
Implant Wear
This year’s combined Orthopaedic Research Society/American 
Academy of Orthopaedic Surgeons symposium dealt with 
clinical, engineering, and biological issues related to implant 
wear. This symposium complemented a recent publication by 
the Academy and the National Institutes of Health on implant 
wear1. The manifestations of wear of total hip and knee re-
placements have been well documented in the past decade. 
Most commonly, osteolysis progresses in a slow, “linear” fash-
ion and is not detectable radiographically until five years or 
more postoperatively, when periprosthetic radiolucent zones 
may be observed. Rates of osteolysis as high as 60% have been 
reported in association with certain hip implants2. In addition 
to wear of hip and knee replacements, wear of total shoulder 
and elbow replacements is an emerging problem that should 
be carefully monitored in the future.
Biological Aspects of Wear—Osteolysis
Particle-induced osteolysis is a primary cause of aseptic loos-
ening. A consensus has emerged that the predominant process 
is one of cytokine production in response to phagocytosis of 
implant wear particles resulting in increased proliferation and 
differentiation of osteoclast precursors into mature osteo-
clasts. Several cell types, including macrophages, fibroblasts, 
and osteoblasts, observed in periprosthetic tissues are believed 
to play a role in the osteolytic process. Nevertheless, because 
osteolysis ultimately involves bone resorption, investigators 
have focused on understanding the role of the osteoclast. Re-
cent breakthroughs in the understanding of osteoclast biol-
ogy—namely, the roles of the OPG/RANKL/RANK system in 
mediating osteoclast formation—have been directly relevant 
to the current focus of osteolysis research.
The OPG/RANKL/RANK cytokine system is the pre-
dominant, final mediator of osteoclast formation3,4. This 
system coordinates the interaction between osteoblasts 
and osteoclasts that is necessary for differentiation of pre-
osteoclasts (monocytes and macrophages) into mature, bone-
resorbing osteoclasts. RANK (receptor activator of nuclear 
factor kappa B) is a transmembrane protein expressed on the 
surface of pre-osteoclasts. RANKL (receptor activator of nu-
clear factor kappa B ligand, also known as TRANCE [tumor 
necrosis factor {TNF}-related activation-induced cytokine]) is 
produced by pre-osteoblastic stromal cells and immune cells. 
When RANKL binds to RANK it initiates an intracellular 
signaling cascade that activates, among others, the NF-κB 
(nuclear factor kappa B) pathway and leads to osteoclast dif-
ferentiation. RANKL, in the presence of macrophage colony-
stimulating factor (M-CSF), is sufficient and necessary for 
osteoclast differentiation in vitro. The critical role of RANKL-
RANK binding in vivo is demonstrated by the fact that dele-
tion of either gene results in severely osteopetrotic mice 
devoid of osteoclasts. OPG (osteoprotegerin) is the third 
member of the OPG/RANKL/RANK system. It is a secreted 
decoy receptor (it lacks a transmembrane domain) that is 
synthesized by pre-osteoblastic stromal cells and binds to 
RANKL. OPG-RANKL binding blunts osteoclast differen-
tiation; the critical role of OPG in regulating RANKL-induced 
osteoclastogenesis is demonstrated by the fact that mice 
lacking OPG have severe osteoporosis. In summary, pre-
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osteoblast/stromal cells can mediate osteoclast formation by 
controlling the levels of available RANKL on the basis of the 
ratio of OPG/RANKL. An increase in this ratio leads to in-
creased OPG-RANKL binding and reduces the bioavailable 
RANKL that is able to bind to RANK, thereby decreasing os-
teoclast differentiation. A decrease in this ratio leads to de-
creased OPG-RANKL binding and increased RANKL available 
to bind to RANK and activate the critical pathway for forma-
tion of mature osteoclasts. Preliminary evidence that the 
OPG/RANKL/RANK pathway is a critical factor in the devel-
opment of clinical osteolysis has come from reports that de-
tectable levels of messenger RNA for RANKL, RANK, and 
OPG have been found in tissue adjacent to loose implants; ad-
ditional studies with suitable control tissue are needed to con-
firm these observations.
Many upstream factors can influence osteolysis. Of 
these factors, TNF-α is recognized as a critical cytokine in 
mediating osteoclastogenesis following exposure to implant 
particles. Using a model in which the calvariae of mice were 
exposed to particles of implant materials (titanium, poly-
methylmethacrylate, etc.), several investigators demonstrated 
that rapid osteoclastogenesis and bone erosion result as TNF-
α levels are increased. Recently, this process was shown to 
occur through activation of the NF-κB intracellular pathway5, 
indicating a link between the OPG/RANKL/RANK system, 
TNF-α, and particle-induced osteolysis.
Therapeutic Targets in Osteolysis 
Will the breakthroughs in the understanding of the biological 
mechanisms of particle-induced osteolysis lead to drug treat-
ments that can prevent periprosthetic bone loss? Anti-TNF 
therapies may be effective for treating particle-induced osteol-
ysis, as suggested by their success in treating rheumatoid 
arthritis6. Anti-TNF treatment in the mouse calvarial model of 
particle-induced osteolysis was shown to be only partially ef-
fective in blocking bone loss, a finding that was related to the 
confounding effects of the adenovirus gene-delivery system 
that was used7. Additional studies with nonviral delivery 
methods are needed to determine the efficacy of anti-TNF 
therapy. Promising early findings have been reported with use 
of agents that target the OPG/RANKL/RANK system. Using 
the mouse calvarial model, investigators from the University 
of Rochester reported two approaches that were effective in re-
ducing osteoclastogenesis and bone resorption: OPG gene 
therapy and RANK blockade by a synthetic RANK fusion pro-
tein (RANK:Fc), both of which should work by increasing the 
ratio of OPG/RANKL8. The same research group showed that 
COX-2 (cyclooxygenase-2) plays a role in particle-induced os-
teolysis and that COX-2 inhibitors are therefore potential 
therapeutic agents.
While agents to inhibit TNF-α or to alter the OPG/
RANKL ratio may ultimately prove to be beneficial for the 
treatment of osteolysis, the use of bisphosphonates (which al-
ready have been established to be extremely effective in halting 
osteoporotic bone loss) may provide a more timely option. 
Several animal studies have demonstrated that not only can al-
endronate prevent particle-induced osteolysis but it can also 
reverse bone loss in established osteolysis9. A recent clinical 
trial demonstrated that administration of bisphosphonate in 
the first six months after total hip replacement prevented 
periprosthetic bone loss10. However, the bone loss observed in 
the control group in this study was probably related to acute 
effects of altered stress distribution or to surgical insult rather 
than to particle-induced osteolysis. Nevertheless, taken to-
gether, these studies illustrate the potential of bisphospho-
nates for the treatment of osteolytic bone loss.
Engineering and Material Aspects of Wear
Submicrometer-sized polyethylene particles make up the bulk 
of particulate wear debris found in periprosthetic tissues11. 
Moreover, the incidence and severity of osteolysis have been 
correlated with the amount of polyethylene wear. Thus, the 
major research focus with regard to engineering has been to 
understand the mechanical and material factors that influ-
ence polyethylene wear and to develop alternative processes 
to improve the resistance of polyethylene to wear. In parallel, 
there are continuing efforts to characterize and develop al-
ternatives to the predominant metal-polyethylene bearing, 
including metal-metal, ceramic-polyethylene, and ceramic-
ceramic bearings.
Osteolysis is rare in patients with rates of acetabular 
polyethylene wear of less than about 0.1 mm/yr, which is at 
the lower end of the average reported range of wear rates, 0.1 
to 0.2 mm/yr12. Thus, the “Holy Grail” of implant materials re-
search and development has been to develop alternative poly-
ethylenes that will reduce the average wear rate to below the 
“osteolytic threshold.” Extensive work in the past five to ten 
years has led to the widespread adoption of new processing 
and sterilization protocols for polyethylene used in acetabular 
components for total hip replacement. (It is likely that the 
same or similar processes will soon be available for tibial com-
ponents of total knee replacements.) While the details of the 
processes differ among manufacturers12, the common goal is 
to introduce a controlled, modest level of cross-linking while 
avoiding the detrimental effects of oxidation. Radiation dose 
determines the degree of cross-linking and in turn the resis-
tance to wear. For the enhanced cross-linked polyethylenes 
now available for acetabular components, manufacturers are 
using radiation doses that have been reported to reduce the 
rate of in vitro wear by ≥85% compared with that of nonir-
radiated polyethylene. The magnitude of wear reduction may 
be lower for conditions of third-body wear, although cross-
linking should still be beneficial. 
A concern raised by some investigators is that the im-
provement in wear resistance resulting from elevated cross-
linking comes at the expense of material strength and fracture 
toughness. This concern has particular relevance to knee com-
ponents, which historically have been more susceptible to 
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fracture and fatigue-related damage such as delamination or 
pitting. However, fatigue damage of polyethylene may be 
largely attributable to reduced toughness caused by oxidative 
damage that historically occurred because polyethylene com-
ponents were sterilized by irradiation in air. Because oxidative 
damage is minimized in the new polyethylenes, the reduction 
in toughness due to cross-linking alone may be small enough 
for fracture-related damage not to be an important clinical is-
sue. However, only long-term clinical results will provide an-
swers to the questions of whether elevated cross-linking of 
polyethylenes will lower wear rates in vivo and, most impor-
tantly, whether it will reduce the incidence of osteolysis and 
aseptic loosening.
Mouse Models in Orthopaedic Research
The increasingly routine use of murine models in musculo-
skeletal research represents a revolution that has taken place in 
the last decade. Mouse studies are generally of two types. In 
the first, the consequences of targeted mutations that delete 
(knock out) or enhance (overexpress) the function of a partic-
ular gene are examined. The aim of these studies is to deter-
mine relationships between genetic structure and function, 
and they may be useful for identifying the genetic basis of dis-
eases linked to a single (or a few) genes. In the second type of 
study, inbred strains of mice are examined in an attempt to 
map quantitative phenotypic traits (e.g., obesity or bone den-
sity) to particular chromosomal regions13. Genetic analysis of 
mother-daughter pairs and twins has indicated that bone 
mineral density (the clinical standard for diagnosis of os-
teoporosis) is 50% to 70% heritable, and thus researchers have 
been searching in mice for the gene (or, more likely, the genes) 
that control phenotypic traits that might affect bone mineral 
density (and other biomechanically relevant traits such as 
bone size and strength). In either type of study, the choice of a 
relevant phenotype (i.e., which traits will be examined) and 
the techniques for assessing the phenotype are critical and will 
be discussed.
Quantitative Genetics
While some discrete orthopaedic disorders can be linked to a 
single genetic mutation, diseases in which risk is a continuous 
variable (such as osteoporosis) are likely to be influenced by 
multiple genes. Because osteoporosis is clinically diagnosed on 
the basis of bone mineral density, studies in which the aim is 
to find “osteoporosis genes” typically are based on the assess-
ment of bone mineral density. One method for finding genes 
that control bone mineral density is quantitative trait loci 
mapping in mice derived by crossbreeding inbred mouse 
strains. Mice within a given inbred strain (e.g., C57Bl/6J) are 
essentially genetically identical and have a relatively narrow 
distribution of quantitative traits like bone mineral density. By 
crossbreeding two inbred strains that have different traits, an 
F2 (second-generation) population can be created that has a 
random mixture of alleles and a broader distribution of bone 
mineral density. With the use of genetic markers, regions of 
the chromosomes (i.e., quantitative trait loci) that are statisti-
cally associated with higher bone mineral densities in the F2 
mice can be identified. A variation on this approach is to gen-
erate recombinant inbred strains by inbreeding a number of 
the F2 mice; these mice can then be used for refined mapping 
of the chromosomal regions of interest14. Most recently, con-
genic strains in which the quantitative trait loci from a donor 
strain (e.g., a mouse with high bone mineral density) are 
transferred to a recipient strain (e.g., a mouse with low bone 
mineral density) have been developed to further assess 
whether given quantitative trait loci contain a gene or genes 
that regulate bone mineral density15. Together, these quantita-
tive genetics approaches have been used to identify at least 
twenty-eight quantitative trait loci for genes that control bone 
mineral density in mice13. The large number of quantitative 
trait loci identified to date may reflect the fact that bone min-
eral density is under the control of many interacting genes as 
well as the fact that different investigators have used different 
methods for assessing bone mineral density (e.g., assessment 
of volumetric bone mineral density with peripheral quantita-
tive computed tomography compared with assessment of areal 
bone mineral density with dual-energy x-ray absorptiometry) 
and have focused on different skeletal sites (the whole body, 
the spine, the femur, etc.). The fact that different genes may 
control bone mineral density at different skeletal sites high-
lights the complexity of the problem.
Functional Skeletal Phenotype
In recent years, there has been considerable debate about what 
is the most relevant functional phenotype for gene-mapping 
studies related to osteoporosis. As noted above, investigators 
have focused on whole-bone or whole-body bone mineral 
density because of the strong association between bone min-
eral density and fracture risk in humans. However, whole-
bone or whole-body bone mineral density in mice does not 
necessarily relate to femoral neck or lumbar bone mineral 
density in humans. Mouse bones, for example, contain a lower 
proportion of trabecular bone than do human bones. More 
recently, investigators have begun to focus on the “bottom 
line” of skeletal function—i.e., whole-bone strength. To date, 
most biomechanical phenotype studies have focused on test-
ing long bones (e.g., femora) and thus have primarily assessed 
cortical bone. Acceptable techniques for testing long bones in-
clude three-point and four-point bending and torsion16. Ef-
forts to assess sites containing trabecular bone (e.g., vertebral 
bodies and the femoral neck) have also been reported. Because 
of the small size of mouse bones it is not possible to isolate 
trabecular bone, and tests on specimens that contain both tra-
becular and cortical bone are likely to be the only practical op-
tion. To date, no particular testing technique has gained 
widespread acceptance.
When functional skeletal phenotype is assessed, basic 
principles of structural mechanics dictate that two types of 
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data be obtained: whole-bone (structural) mechanical proper-
ties and bone geometric properties. Relevant whole-bone me-
chanical properties (for either bending or torsion of long 
bones) include stiffness, yield load, ultimate load, post-yield 
displacement, and energy to fracture. Relevant geometric 
properties include cortical thickness, endosteal and periosteal 
width, bone area, and bone moment of inertia. Ideally, a third 
type of data—bone material properties (e.g., Young modulus 
and ultimate tensile stress)—would be obtained from inde-
pendent tests. In practice, it is difficult to directly assess mate-
rial properties of mouse bones, and investigators typically 
infer the “effective” material properties by using engineering 
equations along with the whole-bone mechanical properties 
and geometric properties. Armed with data on whole-bone 
strength, size, and estimated material properties, investigators 
are able to synthesize a relatively complete picture of the func-
tional skeletal phenotype. However, numerous examples of in-
complete phenotype assessment can be found in the literature. 
In some cases, geometric data have been presented and used to 
draw conclusions about skeletal strength in the absence of me-
chanical property data. The drawbacks of such an approach 
are becoming more recognized17.
Functional Tissue-Engineering—
the Importance of Mechanical Loading
The development of tissue-engineered products and pro-
cesses in the next decade will likely present an unprecedented 
opportunity for clinicians to expand their treatment options 
for such problems as repair of articular cartilage. Nevertheless, 
many challenges must be overcome before successful long-
term treatments can be made available. A workshop at this 
year’s meeting of the Orthopaedic Research Society focused 
attention on the need to better understand cellular mechan-
otransduction (i.e., how cells respond to physical stimuli) in 
the context of both native and engineered tissues.
With regard to engineered tissues, in vitro physical 
stimuli are relevant as a means to enhance biosynthetic activ-
ity and to promote the formation of a stiffer construct. Both 
fluid flow and dynamic compression have been shown to in-
crease matrix synthesis and enhance stiffness of cartilage 
constructs18. Moreover, mechanical loading can enhance the 
positive effects of biochemical stimuli. In engineered agarose-
chondrocyte constructs, dynamic loading over a five-week 
period in conjunction with treatment with either transform-
ing growth factor-β1 (TGF-β1) or insulin-like growth factor-1 
(IGF-1) resulted in a synergistic enhancement of tissue stiff-
ness that was greater than the sum of the effects of the two 
stimuli applied separately19. This synergistic effect is consistent 
with a similar effect observed in native cartilage explants and 
suggests that the optimal process for producing functionally 
competent constructs will require the coordinated delivery of 
appropriate biochemical and biomechanical stimuli. At the 
time of implantation, cartilage constructs should ideally have 
mechanical properties approximating those of healthy native 
tissue. In particular, the dynamic compressive modulus may 
be the most important functional property because it will de-
termine whether the tissue can sustain cyclic in vivo loading 
without undergoing excessive strain leading to structural deg-
radation and construct failure20. The concept of “functional 
tissue-engineering” has been advocated to highlight that syn-
thetic constructs must replace the mechanical function of the 
native tissues21.
In addition to the use of mechanical loading to enhance 
construct properties in vitro, the cells in the constructs should 
be able to modulate their synthetic activity to reflect the in 
vivo loading environment after implantation. One important 
feature of native tissues (cartilage and bone) is that the cells 
(chondrocytes and osteocytes) are surrounded by a pericellu-
lar matrix that differs from the bulk matrix. (Preliminary data 
indicate that this is also true for tendon fibroblasts.) This peri-
cellular matrix controls cell-matrix interactions and deter-
mines the microenvironment of the cell, including how the 
bulk mechanical stresses and strains are transferred to the cell 
surface. The peak strains at the chondrocyte-matrix interface 
may be twice as high as the average tissue strain, whereas in 
bone the cell strains may be an order of magnitude higher 
than the average tissue strain. These relationships between the 
cell and its surrounding matrix may be difficult to replicate in 
engineered constructs. Cells seeded in artificial matrices may 
not be as responsive to mechanical stimuli as are cells in native 
tissue until they have synthesized a new pericellular matrix18. 
The long-term success of engineered constructs will depend 
largely on their ability to replicate cell-matrix interactions that 
enable cells to respond appropriately to biophysical stimuli.
Development of Cartilage and Bone
Members of the TGF-β superfamily include the bone mor-
phogenetic proteins (BMPs) and growth and differentiation 
factors (GDFs). These potent signaling factors reside in the 
extracellular matrix, can form gradients of morphogenetic 
activity, or can signal to the cell to differentiate, proliferate, or 
die. These growth factors stimulate the differentiation of carti-
lage and bone from uncommitted “stem” cells during organo-
genesis in the embryo and in fracture repair. They are also 
important for the maintenance of cartilage and bone struc-
ture. These tissues have a great deal of extracellular matrix that 
participates in the delivery and storage of growth factors. New 
extracellular matrix molecules like chordin, noggin, and a spe-
cific domain of type-II procollagen bind to and consequently 
participate in localizing and regulating the availability of the 
growth factors.
Insights into the mechanism of bone and cartilage dif-
ferentiation have been provided by a number of investigators 
studying signal transduction and gene transcription. Rik 
Derynk, a developmental biologist from the University of 
California, San Francisco, reported new findings on the regu-
lation of cartilage and bone development by TGF-β signaling. 
Once free from binding proteins, TGF-β stimulates the ex-
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pression of cartilage-specific factors and at the same time 
represses the bone-controlling transcription factor Cbfa1, 
through control of a signal transduction protein, Smad3. The 
differentiation of bone and that of cartilage appear to be mu-
tually exclusive. This was also demonstrated with the tran-
scription factor C/EBP. In independent studies, Jane Lian and 
Gary Stein (University of Massachusetts Medical School, 
Worcester, Massachusetts), investigating bone development, 
and Ken Okazaki and one of us (L.J.S.) (Washington Univer-
sity School of Medicine, St. Louis, Missouri), investigating 
cartilage development, discovered roles for C/EBP in the 
regulation of bone-specific osteocalcin and cartilage-specific 
CD-RAP, respectively. In bone, C/EBP acts as a positive factor 
increasing expression of osteocalcin22, whereas in cartilage, 
C/EBP acts as a negative regulatory factor for CD-RAP and 
type-II collagen23. In fact, studies of transgenic mice have 
shown that C/EBP is highly expressed in muscle and bone and 
is responsible for inhibition of CD-RAP expression in those 
tissues. Therefore, cells express a certain set of regulatory fac-
tors (e.g., the transcription factor Cbfa1 or C/EBP) that work 
together to suppress one phenotype and to enhance another. 
In this case, the same factor, Cbfa1, a positive regulator of 
bone gene expression, is turned off during cartilage differen-
tiation, and high levels of C/EBP enhance bone gene expres-
sion and repress cartilage gene expression.
Yet another new molecule has been found to be neces-
sary for bone differentiation: Osterix24. This molecule was 
found during a screen for bone-specific proteins and, when 
“knocked out” in mice, no bone was formed. The transcrip-
tion factor Osterix appears to act downstream of the tran-
scription factor Cbfa1.
Molecular Biology of Fracture Repair
For the last few years, investigators in this area have begun to 
take a molecular view of fracture-healing. Taking advantage 
of the ability to induce fractures in small animals that was 
pioneered by Thomas Einhorn (Boston Medical Center, Bos-
ton, Massachusetts), researchers have used a combination of 
histology, in situ hybridization to mRNA, and immunohis-
tochemistry to provide a molecular description of events 
taking place within the tissue. Currently, the focus is on the 
use of these models to study factors that may affect bone-
healing. Various methods to augment bone-healing with use 
of BMPs, VEGF (vascular endothelial growth factor), and 
bisphosphonates have been tested and have shown various 
capacities to improve the rate of healing. Of critical impor-
tance is the effect of the new selective nonsteroidal anti-
inflammatory drugs, the COX-2 inhibitors, on bone-healing. 
These inhibitors are widely used to control pain in a variety of 
musculoskeletal conditions, and they account for forty-five 
million prescriptions in the United States alone25. Leonelli et 
al.25 reported that rats given the COX-2 inhibitor rofecoxib 
were more likely to have a nonunion, a malunion, and a larger 
callus than were controls and rats treated with ibuprofen. 
Goodman et al.26 supported these findings by showing that a 
COX-2 inhibitor also inhibited bone ingrowth in an experi-
mental model.
The Genetic Basis for Orthopaedic
Diseases is Beginning to Emerge:
Lessons from Fruit Flies and Nematodes
While the study of fruit flies and nematodes will never be pop-
ular in orthopaedic research laboratories, a growing apprecia-
tion of the basic mechanisms of development has arisen from 
the study of more primitive organisms. Research on multiple 
hereditary exostosis is a good example of how developmental 
biologists and scientists interested in human disease can com-
plement each others’ investigations. The primary insight re-
garding the mechanism of this human disease came from 
studying a disease in the fruit fly (Drosophila) called tout-
velu, in which there is a defect in signaling of the hedgehog 
protein. Signaling of the hedgehog protein is disrupted be-
cause of a mutation in the enzyme necessary for synthesis of a 
proteoglycan that binds to the hedgehog protein for distribu-
tion. In a workshop entitled Genetics of Orthopaedic Disorders, 
Chair Chris Evans stressed the recent headway made in under-
standing the genes involved in controlling some musculoskel-
etal diseases. Multiple hereditary exostosis is characterized by 
osseous outgrowths at the margins of the growth plate. Jac-
queline Hecht (University of Texas Medical School, Houston, 
Texas) presented data showing that the genes that cause multi-
ple hereditary exostosis, called EXT1 and EXT2, encode for 
polymerase enzymes that form the heparin sulfate carbohy-
drates on proteoglycans. The heparin sulfate proteoglycans are 
involved in the control of chondrocyte differentiation by regu-
lation of growth-factor stimulation. In this case, the likely pro-
tein that is misregulated, and causes the growth of exostoses, is 
the hedgehog protein. Abnormal signaling of the hedgehog 
protein, known to be an important regulator of growth-plate 
function, causes further differentiation of growth-plate chon-
drocytes into hypertrophic chondrocytes, which then can be 
mineralized and replaced by bone generated from osteoblasts 
in the vasculature.
Another unforeseen molecular player, the heparin 
sulfate proteoglycan perlecan, is now known to participate 
in skeletal dysplasia of the Silverman-Handmaker type27. In 
fact, while 60% of mice missing this proeoglycan have the 
dysplasia, 40% die during embryogenesis because of defective 
cephalic development. It is very possible that the responsible 
signaling events are the same as those in multiple hereditary 
exostosis, as described above.
The understanding of rare diseases will help to provide 
information that can be applied to all musculoskeletal dis-
eases. Although individually rare, the many different forms, 
taken together, result in a substantial number of affected in-
dividuals with major morbidity and mortality. The rapid ad-
vances in the understanding of the molecular basis for skeletal 
dysplasias have made the classification of diseases difficult. For 
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example, the clinical symptoms of diseases caused by type-II-
collagen mutations can be quite varied; they cannot be clas-
sified only according to the molecular defect. Therefore, a 
new classification of genetic disorders of the skeleton has 
been proposed28. In this system, there is a nosology—a catalog 
of defined entities. This includes a clinical classification, 
focused on age-specific presentations and clinical signs, 
to be of help in the diagnostic approach, and a molecular-
pathogenetic classification based on the genes and pathoge-
netic mechanisms involved. These two classifications will be 
cross-correlated in an electronic database.
Stem Cells
The use of stem cells in research has become a household dis-
cussion. Stem cells have a pluripotent ability to commit to 
specific cell fates. Such flexibility is apparent in the embryonic 
stem cell, which by definition is a precursor of all cells in the 
developed organism. It is less apparent that many other tissues 
have a reserve of “stem” cells with limited but distinct poten-
tial, such as periosteal and perichondrial cells, pericytes from 
blood vessels, stem cells from muscle and fat, and, potentially 
the richest adult source, bone-marrow stem cells. The use of 
these cells and the conditions under which they can differenti-
ate have been intensively investigated recently. Muscle, fat, and 
mesenchymal stem cells from bone marrow can be induced to 
form bone. While it has been known for a while that BMPs 
stimulate bone differentiation, Majumdar et al.29, from Genet-
ics Institute, showed that BMP-2 or BMP-9 together with a 
relatively new cytokine, IL-11 (interleukin-11), function to 
promote chondrogenesis in these cells. IL-11 is a member of 
the IL-6 family and has been found to be effective in preven-
tion of inflammatory bowel disease.
Gene Therapy
Bone
The advantage of gene therapy is that when the gene is resi-
dent in the cell, the products of gene expression can be made 
and distributed in situ. This therapy may be applied to cells 
while they are in the body (in vivo) or to cells or pieces of tis-
sue that have been removed from the body (ex vivo). More 
than fifty papers on this valuable technique were presented at 
the meeting of the Orthopaedic Research Society in 2002. Al-
though none are used yet in the clinical setting, the induction 
of bone formation through gene therapy may be on the hori-
zon. In addition to studies involving the growth factors BMP-
2 and BMP-7 (OP-1), the induction of bone with use of LIM 
mineralization protein-1 appears to be feasible30. LIM miner-
alization protein-1 is a transcription factor that may function 
through stimulation of endogenous BMPs. While the methods 
of gene delivery have not been well defined, the exogenous de-
livery of genes known to stimulate repair or replacement of 
bone will likely become a common method for stimulation of 
cell metabolism. In a novel technique, muscle stem cells were 
used to deliver BMP-4 in a nonhealing skull defect. The gene 
for BMP-4 was cloned into a retrovirus and transduced into 
the muscle cells ex vivo, after which the cells were implanted 
into the defect31. Use of the retrovirus holds promise as a safe 
method in humans as it is not antigenic and therefore pro-
vides a low immunological risk to the patient.
Other Skeletal Tissues
Adenoassociated virus vectors are being used to transduce hu-
man meniscal cells and even meniscal explants in vitro. The 
efficiency of transduction has been quite high, and future ex-
periments will likely focus on the delivery of specific genes. 
IGF-1 gene therapy has proved productive for inducing heal-
ing of cartilage in horses and, in conjunction with dynamic 
loading, in bovine cartilage discs. The use of BMP-2 and 
BMP-4 for induction of cartilage-healing has been examined 
as has gene expression of BMP-2 and other growth factor 
genes in nucleus pulposus.
Osteoarthritis and Biomarkers
Great headway continues to be made in the understanding of 
matrix degradation in osteoarthritis. The recent discovery of 
specific “aggrecanases” and “versicanases” has revealed the 
participation of an entire group of enzymes that cleave pro-
teoglycans in tissue. These enzymes, in addition to the matrix 
metalloproteinases that have been studied for decades, may be 
responsible for the initial cleavages in the important pro-
teoglycans. Recently, the attention of investigators has turned 
to the factors that are responsible for activation of these de-
structive enzymes and how they might function in vivo. Con-
troversial at this point is the timing of degradation by specific 
enzymes during the course of progression of osteoarthritis 
and which molecules are initially targeted. Resolution of the 
control of these pathways will be the focus of the next few 
years of research as headway is made in understanding the 
progression of osteoarthritis.
Recognition that osteoarthritis progresses slowly over a 
long period has stimulated research into methods of detec-
tion of the stage of osteoarthritis and the potential for predic-
tion of short and long-term outcomes. Certainly, if the disease 
can be better defined, interventional therapies short of joint 
replacement could be developed and implemented. Various 
methods are being used to determine the state of cartilage and 
the rate of disease progression. Mechanical, imaging, and bio-
logical parameters are under investigation. Camacho et al.32 
are using a fiberoptic probe for detection of degenerative 
cartilage, while others are using pressure probes to detect 
mechanical changes in the cartilage, or serum markers for col-
lagen and aggrecan metabolism. With one promising method, 
changes in the rate of synthesis are compared with the rate of 
degradation so that when repair slows down and degradation 
increases, the molecular changes can be monitored in urine 
and serum over time, predicting the rate of cartilage loss33.
Finally, as there have been so many advances in ortho-
paedic research recently, the reader is referred for further in-
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depth study to the Transactions of the Orthopaedic Research So-
ciety, which are available on the web site www.ors.org, and as a 
CD-ROM containing the abstracts, available from the Society 
by telephone (847-698-1625).
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